Lilly Oncology Taps NYU Professor

(photo courtesy New York University)

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has selected Leena Gandhi to lead immuno-oncology medical development efforts at Lilly Oncology. Gandhi currently serves as director of thoracic medical oncology at the New York University School of Medicine.

Gandhi will begin her new role June 25. At Lilly, she will be responsible for leading a team of scientists overseeing the Lilly Oncology immunotherapy portfolio. 

"Dr. Gandhi is highly regarded for her experience in thoracic oncology and immunotherapy, having worked in early drug development at Dana-Farber Cancer Institute and now leading the Thoracic Medical Oncology Program at NYU," said Kimberly Blackwell, vice president of early phase development and immuno-oncology at Lilly. "We know that her expertise and innovative thinking will lead to significant progress for patients facing cancer through the use of immune therapies."

Gandhi is also an associate professor of medicine at the NYU School of Medicine.